Jason Yau

People Science is a direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines. The company is dedicated to the public good and is poised to revolutionize the alternative medicine landscape with its data-driven approach - empowering patients, consumers, providers, and scientists to collectively improve health outcomes. People Science is powered by our proprietary software technology called CHLOE (Consumer Health Learning and Organizing Ecosystem) that integrates clinical care with scientific research. The People Science research marketplace offers a new model of popular access, research participation, and education - networking patient communities with healthcare providers and scientists to provide scientifically proven optimal care in alternative medicines. Companies that make alternative medicines will hire People Science to study their medicines and to differentiate their products with the People Science Seal of Approval in the rapidly expanding alternative medicines market. Examples of alternative medicines include medical cannabis and cannabinoids, microbiome and probiotic interventions, functional medicine and nutritional supplements, and psychedelic medicines. People Science is a for-profit Public Benefit Corporation and we are seeking partners, clients, and investors who are aligned with our long-term vision and the value of this venture to society.

Menlo Ventures is a venture capital firm that strives to have a positive impact on everything we do. That’s why we support businesses—including Abnormal Security, Benchling, Carta, Chime, Harness, Pinecone, Roku, Rover, Siri, and Uber—that are reimagining life and work for the better. Over 47 years, we’ve grown a portfolio that includes more than 80 public companies, over 165 mergers and acquisitions, and $5.8 billion under management. We invest at every stage and in every sector, with expertise in consumer, enterprise, and healthcare. From developing market strategies to creating communities, we provide real impact where entrepreneurs need it most. When we’re in, we’re ALL IN.

Glynn 100 is a curated network of leaders within Technology, IT, Security, Finance, Marketing, and Human Resources at Glynn Capital. Glynn Capital is focused on investments in leading private and public technology growth companies (www.glynncapital.com). This network does not provide investment advice. This page is for informational purposes only and no statement is to be construed as an offer to sell or a solicitation to buy any security, investment product or service.

People Science is a direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines. The company is dedicated to the public good and is poised to revolutionize the alternative medicine landscape with its data-driven approach - empowering patients, consumers, providers, and scientists to collectively improve health outcomes. People Science is powered by our proprietary software technology called CHLOE (Consumer Health Learning and Organizing Ecosystem) that integrates clinical care with scientific research. The People Science research marketplace offers a new model of popular access, research participation, and education - networking patient communities with healthcare providers and scientists to provide scientifically proven optimal care in alternative medicines. Companies that make alternative medicines will hire People Science to study their medicines and to differentiate their products with the People Science Seal of Approval in the rapidly expanding alternative medicines market. Examples of alternative medicines include medical cannabis and cannabinoids, microbiome and probiotic interventions, functional medicine and nutritional supplements, and psychedelic medicines. People Science is a for-profit Public Benefit Corporation and we are seeking partners, clients, and investors who are aligned with our long-term vision and the value of this venture to society.

Science 37 is a clinical research site that delivers trials directly to patients homes. We accelerate research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.